Table 1.

Baseline Patient Characteristics Before Propensity Score Adjustments, by Treatment Group.

Variable	Bisphosphonates (N=39493)	Teriparatide (N=550)	P-value
Age (%)			0.089
<65	8.78	11.45
65–74	47.54	46.00
≥75	43.68	42.55
Race (%)			<0.001
White	77.30	78.00
Black	6.17	2.91
Asian	5.60	2.73
Hispanic	9.44	14.73
Native American	0.48	0.91
Other	1.03	0.70
Medicaid eligibility (%)	36.16	45.82	<0.001
History of hip fracture (%)	4.66	11.80	<0.001
History of vertebral fracture (%)	5.50	19.10	<0.001
History of fracture of radius, ulna or carpal bones (%)	3.20	5.27	0.006
History of other upper limb fractures (%)	3.24	5.27	0.008
History of other lower limb fractures (%)	6.46	13.27	<0.001
History of CMS priority cancera (%)	10.61	7.09	0.008
No. of CMS priority comorbiditiesb (%)			<0.001
0–2	46.11	35.45
3–5	36.96	39.27
≥6	16.93	25.27
Time between diagnosis and drug initiation			<0.001
≤2 months	51.44	34.36

NOTES:

Abbreviations: CMS= Centers for Medicare and Medicaid Services.

^aCMS priority types of cancer include breast cancer, colorectal cancer, endometrial cancer and lung cancer.

^bThe number of other CMS priority comorbidities was calculated as the sum of previous history of acute myocardial infarction, atrial fibrillation, Alzheimer’s disease, related disorders or senile dementia, cataract, chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, depression, diabetes, glaucoma, ischemic heart disease, history of stroke or transient ischemic attack, and rheumatoid arthritis or osteoarthritis.